a public good project by the
Synthesis
Company
of California

© 2026

Ashok Gupta | doi.page

0 works0 citations0 h-index

Ashok Gupta

NIMS University(IN)Sharda University(IN)

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cytokine Signaling Pathways and Interactions, Bladder and Urothelial Cancer Treatments, Cancer Genomics and Diagnostics

Most-Cited Works

→ Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer(2012)12,531 cited
→ Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer(2012)7,941 cited
→ Nivolumab plus Ipilimumab in Advanced Melanoma(2013)4,207 cited
→ Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab(2014)2,198 cited
→ Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer(2015)1,189 cited
→ Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma(2017)842 cited

→ Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer(2016)

840 cited

→ Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study(2016)590 cited

→ Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial(2020)489 cited

→ Fungal rhinosinusitis(2009)463 cited